CVS Health reported more than $4.5 billion in 2024 profits including $1.6 billion in the fourth ... [+] quarter as the health insurer worked to overcome rising medical expenses from patients in its health insurance plans, the company said Feb. 12, 2025. In this photo is a sign marking the location of a CVS pharmacy May 5, 2004 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)Getty ImagesCVS Health reported $4.6 billion in 2024 profits including $1.6 billion in the fourth quarter as the company worke ...

CVS Health Corp CVS will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 94 cents in EPS and $97.20 billion in revenues as the company reports before market hours.The stock is down 29.78% over the past year, up 22.72% YTD.Let’s look at what the charts indicate for CVS stock and how the stock currently maps against Wall Street estimates.Read Also: Wall Street’s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend YieldsCVS Stock Chart Bullish Ahea ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Analysts on Wall Street project that CVS Health (CVS) will announce quarterly earnings of $0.89 per share in its forthcoming report, representing a decline of 58% year over year. Revenues are projected to reach $97.06 billion, increasing 3.5% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 1.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timefr ...

On Jan. 30, Walgreens Boots Alliance, a leading pharmacy chain, announced that it was suspending its dividend program, which had been active for over 90 years. This longtime dividend payer is suffering under the weight of financial troubles and had previously resorted to decreasing its payouts.Walgreens isn't the only dividend-paying pharmacy chain whose financial results haven't been strong recently. CVS Health (CVS -2.60%) is in the same boat. Should investors be worried about CVS also decreasing or endin ...

Value-focused billionaire asset managers are trading out pricey stocks for perceived-to-be safe, income-producing, brand-name businesses.For more than two years, the bulls have been running wild on Wall Street. Since 2023 began, the ageless Dow Jones Industrial Average, benchmark S&P 500 (^GSPC 0.72%), and growth-powered Nasdaq Composite have soared by 34%, 57%, and 88%, respectively, through the end of January 2025.While rising tides have given investors plenty of reason to smile, it's also made the stock ...

Volatility is plaguing Wall Street in light of President Donald Trump's tariffs. Regardless of what's up next, traders can take advantage of Schaeffer’s Senior Quantitative Analyst Rocky White's list of 25 worst S&P 500 Index (SPX) stocks for February to know which stocks to avoid over the coming weeks. CVS Health Corp (NYSE:CVS) is among them, and warrants a closer look.According to White, CVS averaged a 4.3% loss in February in the last decade, settling higher only three times during that period. The stoc ...

CVS Health Corporation (CVS) is scheduled to report fourth-quarter 2024 results on Feb. 12, before the opening bell.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, the company’s adjusted earnings of $1.09 exceeded the Zacks Consensus Estimate by 1.87%. CVS Health beat estimates in three of the trailing four quarters and missed in one, the average negative surprise being 2.50%.The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $97.06 billio ...

Core Viewpoint - CVS Health is a significant player in the healthcare sector, combining pharmacy retail, pharmacy benefits management, and health insurance services through its acquisition of Aetna in 2018 [1] Group 1: Stock Performance and Valuation - Despite its strong position in the healthcare industry, CVS stock has lost nearly 50% of its value over the past three years [2] - The current low valuation may prompt investors to consider whether it is an opportune time to invest, especially ahead of the year-end earnings report scheduled for February 12 [3] Group 2: Earnings and Management Changes - CVS has underperformed in recent quarters, consistently missing analyst expectations and lowering its guidance multiple times [5] - The new CEO, David Joyner, took over in October, and the upcoming earnings report will be the first full quarter under his leadership, making it crucial for investors to assess his long-term strategy [7] Group 3: Strategic Considerations - Investors should focus on the CEO's vision and potential strategic changes, such as reducing the dividend, store count, or selling assets to create a leaner operating model [8] - CVS reported sales of nearly $370 billion over the past four quarters, but profits were just over $5 billion, indicating a need for significant operational improvements [8] Group 4: Investment Approach - Given the current uncertainties surrounding CVS, it is advised that investors adopt a wait-and-see approach rather than rushing to buy shares before the earnings report [10][11]

Core Viewpoint - CVS Health has shown significant stock performance recently, with a +27.9% return over the past month, outperforming the S&P 500 composite's +1.1% and the Zacks Retail - Pharmacies and Drug Stores industry's +24.9% [2] Earnings Estimates - CVS Health is expected to report earnings of $0.89 per share for the current quarter, reflecting a year-over-year decline of -58%. The consensus estimate for the current fiscal year is $5.18, indicating a -40.7% change year-over-year [5] - For the next fiscal year, the consensus earnings estimate is $5.97, which represents a +15.3% increase compared to the previous year [6] - The Zacks Rank for CVS Health is 5 (Strong Sell), indicating a negative outlook based on recent earnings estimate revisions [7] Revenue Growth Forecast - The consensus sales estimate for CVS Health for the current quarter is $97.06 billion, showing a year-over-year increase of +3.5%. For the current and next fiscal years, the sales estimates are $372.16 billion and $386.77 billion, reflecting +4% and +3.9% changes, respectively [9] Last Reported Results - In the last reported quarter, CVS Health achieved revenues of $95.43 billion, a +6.3% increase year-over-year. The EPS was $1.09, down from $2.21 a year ago. The revenue exceeded the Zacks Consensus Estimate by +2.75%, and the EPS surprise was +1.87% [11] Valuation - CVS Health is graded A in the Zacks Value Style Score, indicating that it is trading at a discount compared to its peers [15]